Latest News and Press Releases

Norwood, MA, May 19, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical-stage drug development company pioneering transformative...

First study to explore potential benefit of a cannabinoid receptor type 2 agonist in SLEStudy sponsored and funded by the National Institute of Allergy and Infectious Diseases through the Autoimmunity...

 ●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021  ●Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with...

•   Company to host conference call and webcast on Monday, March 15, 2021 at 8:30 a.m. ET Norwood, MA, March 08, 2021 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)...

Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background...

As previously reported, lenabasum did not meet its primary efficacy endpoint in the studyLenabasum was well tolerated with no new safety findingsExploratory post-hoc analyses revealed unexpectedly low...

Preliminary baseline subject demographics and disease characteristics in a Phase 3 clinical trial of the safety and efficacy of lenabasum in dermatomyositis (DETERMINE)Cannabinoid receptor type 2...

Company is restructuring with the goal of extending cash runway to mid-2022Workforce to be reduced by 54%Company to focus on completing Phase 3 dermatomyositis study and advancing preclinical pipeline...

Topline data showed no significant differences in the primary and secondary endpoints when comparing lenabasum to placebo, both added to background drug therapyUnprecedented improvement was observed...

RESOLVE-1 Phase 3 study of lenabasum for treatment of systemic sclerosis on schedule for topline data this summerPhase 2b study of lenabasum for cystic fibrosis topline results on schedule in Q3...